InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | EVNIN LUKE | Director | Sale | 56.6K | $0.69 | $39K | 1.95M | View ↗ | |
| 2026-04-28 | EVNIN LUKE | Director | Sale | 95.4K | $0.73 | $70K | 2.01M | View ↗ | |
| 2026-04-27 | EVNIN LUKE | Director | Sale | 53.9K | $0.85 | $46K | 2.11M | View ↗ | |
| 2026-01-16 | EVNIN LUKE | Director | Sale | 38.8K | $0.54 | $21K | 2.16M | View ↗ | |
| 2026-01-15 | EVNIN LUKE | Director | Sale | 37.4K | $0.55 | $21K | 2.20M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Collaboration revenue | $0-100.0% | $1.9M-90.5% | $19.9M+21.6% | $16.4M |
| Research and development | $44.8M-20.6% | $56.4M+35.1% | $41.8M-22.3% | $53.8M |
| General and administrative | $15.8M-16.8% | $19.0M+2.0% | $18.7M-0.1% | $18.7M |
| Total operating expenses | $60.7M-19.6% | $75.5M+24.9% | $60.4M-16.6% | $72.5M |
| Operating loss | -$60.7M+17.6% | -$73.6M-81.7% | -$40.5M+27.7% | -$56.1M |
| Interest income | $3.1M-53.4% | $6.7M-10.0% | $7.4M+288.7% | $1.9M |
| Interest expense | -$5.3M-13.3% | -$4.7M-48.3% | -$3.1M | $0 |
| Loss on extinguishment of debt | $0+100.0% | -$553K | $0 | — |
| Other income, net | $2.0M+25.1% | $1.6M | — | — |
| Total other (expense) income | -$145K-104.7% | $3.1M | — | — |
| Net loss | -$60.8M+13.7% | -$70.5M-88.7% | -$37.4M+30.6% | -$53.8M |
| Net loss per common share, basic (in usd per share) | -$1K+19.0% | -$2K | — | — |
| Net loss per common share, diluted (in usd per share) | -$1K+18.4% | -$2K | — | — |
| Weighted average common shares outstanding, basic (in shares) | $46.02B+6.2% | $43.33B+21.6% | $35.65B+23.5% | $28.86B |
| Weighted average common shares outstanding, diluted (in shares) | $46.81B+6.7% | $43.86B+23.0% | $35.65B+23.5% | $28.86B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Werewolf Therapeutics GAAP EPS of -$0.20 beats by $0.14
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics announces plan to explore strategic alternatives
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives